Embattled GlaxoSmithKline hit with another fraud probe

Britain's fraud agency on Tuesday said it had launched a probe into pharmaceutical giant GlaxoSmithKline, which is already subject of a series of investigations into alleged staff corruption.

The Serious Fraud Office (SFO) confirmed it had opened a "formal " into the London-based drugs manufacturer's commercial practices.

"GSK is committed to operating its business to the highest ethical standards and will continue to cooperate fully with the SFO," said a company spokesman, without providing further details.

GSK last month said first-quarter revenues had fallen 10 percent to £5.6 billion (6.9 billion euros, $9.4 billion) after a Chinese impacted sales growth at the company's emerging markets division.

In a further blow, Polish prosecutors in April said they had extended a probe into allegations that GSK bribed doctors into promoting one of its drugs.

The company is also investigating alleged corruption by staff at its pharmaceuticals division in Iraq.

GSK last year admitted that senior employees appeared to have breached Chinese law after Beijing authorities alleged that staff had bribed government officials, pharmaceutical industry groups, hospitals and doctors to promote sales.

add to favorites email to friend print save as pdf

Related Stories

Probe-hit GlaxoSmithKline announces profits slump

Apr 30, 2014

GlaxoSmithKline, the British drugs giant facing a series of probes into alleged staff corruption, announced sliding profits on Wednesday, one week after unveiling a group makeover.

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

Jul 24, 2014

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

User comments